Support Cancer Treatment Fairness

BACKGROUND:
  • ASCO strongly supports the Cancer Drug Parity Act, bipartisan legislation introduced in the U.S. House that would require private health insurance plans offering intravenous (IV) cancer drug benefits to provide parity in patient cost sharing between traditional IV drugs and oral anticancer drugs
  • Scientific advancements increasingly allow oncologists to treat cancer with oral anti-cancer medications that often provide clinical advantages over traditional forms of cancer medication
  • Some health plans impose higher cost sharing requirements (copayments, coinsurance, etc.) on cancer patients for oral cancer drugs
CURRENT STATUS:
  • H.R. 1409 was introduced by Representatives Leonard Lance (R-NJ) and Brian Higgins (D-NY)
  • 126 Current Cosponsors can be found here: https://www.congress.gov/bill/115th-congress/house-bill/1409/cosponsors 
  • Senate companion legislation has yet to be introduced
  • Ask your lawmaker to cosponsor the Cancer Drug Parity Act (H.R. 1409), which would ensure that patient cost sharing for orally administered and self-injectable cancer drugs is no less favorable than for traditional IV drugs

Act Now! Send a Letter!

First Name

Last Name

Home Address

Email